PRECISECORE 10 MM BIOPSY DEVICE- 14GA X 5 CM MODEL 670514, 671014, 670518 671018, 670520

K093399 · Inrad · KNW · Nov 19, 2009 · Gastroenterology, Urology

Device Facts

Record IDK093399
Device NamePRECISECORE 10 MM BIOPSY DEVICE- 14GA X 5 CM MODEL 670514, 671014, 670518 671018, 670520
ApplicantInrad
Product CodeKNW · Gastroenterology, Urology
Decision DateNov 19, 2009
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 876.1075
Device ClassClass 2

Intended Use

The device is intended for use in obtaining biopsies from soft tissues such as liver, breast, kidney, prostate, spleen, lymph nodes and various soft tissue tumors. For breast biopsy this product is for diagnosis only - not for therapeutic use.

Device Story

PreciseCore™ Biopsy Device is a sterile, disposable, mechanically actuated instrument for soft tissue biopsy. Device features stainless steel cutting cannula and stationary stylet; design allows tissue acquisition without advancement of needle set beyond visualized tip. Operated by clinicians in clinical settings. Device captures tissue samples for diagnostic evaluation. Benefit includes precise tissue sampling with reduced risk of injury to structures beyond the target site due to stationary stylet design.

Clinical Evidence

Bench testing only; performance testing confirmed that the quality of samples obtained with the PreciseCore™ Biopsy Device is equivalent to that of the predicate device.

Technological Characteristics

Sterile, disposable biopsy instrument. Components: stainless steel cutting cannula and stylet, plastic housing. Mechanically actuated. Stationary stylet design. No electronic or software components.

Indications for Use

Indicated for patients requiring soft tissue biopsies, including liver, breast, kidney, prostate, spleen, lymph nodes, and soft tissue tumors. For breast biopsy, use is restricted to diagnostic purposes only.

Regulatory Classification

Identification

A gastroenterology-urology biopsy instrument is a device used to remove, by cutting or aspiration, a specimen of tissue for microscopic examination. This generic type of device includes the biopsy punch, gastrointestinal mechanical biopsy instrument, suction biopsy instrument, gastro-urology biopsy needle and needle set, and nonelectric biopsy forceps. This section does not apply to biopsy instruments that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K093399 #### SECTION 5: 510(k) SUMMARY Image /page/0/Picture/2 description: The image shows the logo for INRAD Optics. The logo consists of a square with a checkmark inside, followed by the word "INRAD" in large, bold letters. A small "R" in a circle is located to the right of the letter "D". NOV 1 9 2009 November 12, 2009 ## Contact Information Melissa Lalomia Director of Quality & Regulatory Affairs Phone: 616-301-7800, ext. 102 616-301-7799 Fax: E-mail: mlalomia@inrad-inc.com ## Company Information Inrad, Inc 4375 Donker Court SE Kentwood, MI 49512 616-301-7800 Phone: 616-301-7799 Fax: # Device Name(s) PreciseCore™ Biopsy Device Device Summary Trade or Proprietary Name: PreciseCore™ Biopsy Device Common or Usual Name: Classification Name: Biopsy Instrument Gastroenterology-urology biopsy instrument (21 CFR 876.1075, Product code KNW) # Name of Predicate(s) or Legally Marketed Device(s) K994272 – Promex Automated Core Biopsy Device Also known as: - > SABD™ Disposable Core Biopsy System(US Biopsy is a division of Promex Technologies) - > Inrad® AccuCore Single Action Core Biopsy Device (manufactured for Inrad by US Biopsy) #### Section 5 - 1 INRAD, INC. - CONFIDENTIAL {1}------------------------------------------------ ### Device Description The PreciseCore™ Biopsy Device is a sterile, disposable device which features a stainless steel cutting cannula and stylet. The device is comprised of a plastic housing that contains the mechanically actuated components. The stylet of the device is stationary, therefore acquiring tissue without an advancement of the needle set beyond the visualized tip. ### Indications for Use The device is intended for use in obtaining biopsies from soft tissues such as liver, breast, kidney, prostate, spleen, lymph nodes and various soft tissue tumors. For breast biopsy this product is for diagnosis only - not for therapeutic use. #### Substantial Equivalence The PreciseCore™ Biopsy Device has the same intended use as the Inrad® AccuCore Single Action Core Biopsy Device and US Biopsy SABD. The device and the predicate devices have the same technological characteristics in terms of design and materials. #### Performance Testing Summary Performance testing confirms that the quality of samples obtained with the PreciseCore™ Biopsy Device is equivalent to that of the predicate device. #### Section 5 - 2 {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract image of an eagle or bird-like figure, depicted with stylized lines to represent its wings and body. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-066-0609 Silver Spring, MD 20993-0002 Inrad, Inc. % Ms. Melissa Lalomia Director of Quality and Regulatory Affairs 4375 Donker Court SE Kentwood, Michigan 49512 # NOV 1 9 2009 Re: K093399 Trade/Device Name: PreciseCore™ Biopsy Device Regulation Number: 21 CFR 876.1075 Regulation Name: Gastroenterology-urology biopsy instrument Regulatory Class: Class II Product Code: KNW Dated: October 28, 2009 Received: November 2, 2009 Dear Ms. Lalomia: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 {3}------------------------------------------------ Page 2 - Ms. Melissa Lalomia CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050, If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrl/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Sincerely yours, Mark A. Millman Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ### SECTION 4: INDICATIONS FOR USE STATEMENT # Indications for Use 510(k) Number (if known): Device Name: Indications for Use: PreciseCore™ Biopsy Device K0933999 The device is intended for use in obtaining biopsies from soft tissues such as liver, breast, kidney, prostate, spleen, lymph nodes and various soft tissue tumors. For breast biopsy this product is for diagnosis only - not for therapeutic use. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use _ (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Naf Rkble far 1 km (Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K093399 Section 4 - 1 INRAD, INC. - CONFIDENTIAL
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%